THERAPY & TREATMENT
Management and Care of MPS & Related Diseases
Mucopolysaccharide & related diseases are complex, multi-systemic diseases and their management and care can be extremely complicated. Due to increased research, new treatments have become available for some types of MPS; however, for some types of MPS & related diseases, treatment remains symptomatic in nature. Please visit our online store for a full listing of our educational booklets, and visit the links section of our website (under support) for links to many informative websites.
Therapies for MPS & Related Diseases
Last updated December 2013
Aldurazyme (laronidase) enzyme replacement therapy (ERT) was licensed for use by Health Canada on May 31, 2004, for long-term treatment in patients with a confirmed diagnosis of MPS I, to treat the non-neurological manifestations of the disease. For more information, please visit www.aldurazyme.com.
The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Torrence, California, and the University of Minnesota are collaborating on three studies of intrathecal enzyme replacement therapy (ERT) for patients with MPS I:
MPS I Intrathecal ERT for Spinal Cord Compression:
Enzyme replacement therapy (ERT) has been developed for MPS I. ERT helps many physical ailments due to the disease, but does not treat the central nervous system due to inability to cross the blood brain barrier. The purpose of this study is to test delivery of ERT to the spinal fluid via intrathecal (IT) injection in patients with MPS I to find out whether giving ERT directly into the spinal canal can help reduce spinal cord compression and provide an alternative to surgery.
Study participants will have:
- up to 16 IT ERT treatments given one to three months apart over one-and-a-half years
- physical examinations (general and neurologic)
- other diagnostic tests
- reimbursement of travel expenses
MPS I Intrathecal ERT for Cognitive Decline:
The purpose of this research study is to find out whether giving ERT with Aldurazyme as an injection directly into the cerebral spinal fluid can stabilize or improve cognitive decline in patients who have MPS I. The term “cognitive decline” refers to a change for the worse in the ability to think and learn.
Study participants will have:
- up to 10 treatments given one to three months apart over two years (treatment group) or four treatments given three months apart beginning at month 12 (control group)
- physical examinations (general and neurologic)
- neuropsychological testing for cognitive decline and MRI of the brain
- reimbursement of travel expenses
Additional information can be found at www.clinicaltrials.gov; search under “mucopolysaccharidosis” or contact
Principal Investigator Dr. Patricia Dickson at 310-781-1399 or email@example.com.
MPS I Intrathecal ERT for Children Being Considered for Transplant:
The University of Minnesota in Minneapolis has obtained FDA approval for the delivery of laronidase into the spinal fluid of children with MPS I (Hurler syndrome)being considered for marrow/cord blood transplantation at the University of Minnesota. The goal of these studies is to decrease the neuropsychologic decline that is generally observed in children with Hurler from the time the patients are initially evaluated to the time they are one year from transplantation.
The study will involve four doses of laronidase given during a lumbar puncture (LP) approximately three months before transplantation, at the time of admission to the hospital for the transplant, three months after the transplant, and six months after the date of the transplant. The LP's are performed with sedation.
Principal Investigator Dr. Paul Orchard can be contacted for more information at 612-626-2961 or firstname.lastname@example.org.
Chaperone-Advanced Replacement Therapy (CHART™) program for Mucopolysaccharidosis Type I (MPS I):
Amicus Therapeutics announced in June 2013 a preclinical Chaperone-Advanced Replacement Therapy (CHART™) program for Mucopolysaccharidosis Type I (MPS I). Amicus is developing a proprietary human recombinant IDUA (rhIDUA) enzyme co-formulated with a novel pharmacological chaperone as a next generation therapy for MPS I. Click here for more information.
On June 15, 2007 Elaprase enzyme replacement therapy (ERT) was approved by Health Canada for the treatment of MPS II. For more information, please visit www.hunterpatients.com.
Shire MPS II Intrathecal Study:
A Phase I/II (Safety/Dosage) trial using investigational idursulfase—IT for the treatment of MPS II via an intrathecal drug delivery device (IDDD) has been completed and an extension study is ongoing. A global Phase II/III study designed to evaluate the effect on early cognitive and functional stabilization after treatment with idursulfase—IT, in conjunction with intravenous idursulfase, is in the planning stages, and is currently projected to open for enrollment in Europe in 2014. A longitudinal, observational study is ongoing, and is currently enrolling boys with MPS II, ages 2 to 13. Click here for more details on these and other Shire-sponsored studies.
Phase I/II Study of ERT for MPS IIIA:
Shire has completed a safety and dose-ranging study to evaluate the delivery of investigational intrathecal recombinant human heparan N-sulfatase (rhHNS) via an IDDD in 12 patients with MPS IIIA, and an extension study is ongoing at Emma Children’s Hospital, Academic Medical Center in The Netherlands under the direction of Dr. Frits Wijberg, and St. Mary’s Hospital in Manchester, UK under the direction of Dr. Simon Jones. Shire’s natural history studies of individuals with MPS IIIA and MPS IIIB are both closed to enrolment. Click here for more details on Shire’s programs.
Gene Therapy Study to be conducted at Nationwide Children’s Hospital:
Click here to read more about this study from Nationwide, and here to read the Canadian press release.
Please click here to read about various natural history studies being conducted by Nationwide Children’s Hospital, Shire, Synageva and The Neurodevelopmental Function in Rare Disorders (NFRD) Program at the University of North Carolina at Chapel Hill.
Brian Bigger’s research team from the University of Manchester’s MPS Stem Cell Research Laboratory found that “Genistein may prove useful as a substrate reduction agent to delay clinical onset of MPSIIIB and, due to its multimodal action, may provide a treatment adjunct for several other neurodegenerative metabolic diseases.” Please click here for more information from the UK MPS Society.
A clinical trial of high-dose Genistein Aglycone is taking place in Manchester (UK), with Simon Jones as the principal investigator. Frits Wijburg is also conducting a Genistein study at the Amsterdam Medical Centre.
Click here to view a video (from Dec 2013) featuring Dr. Brian Bigger explaining why this trial is so important.
MPS IIIB AAV gene therapy clinical trial:
Dr. J. M. Heard is leading a MPS IIIB AAV gene therapy clinical trial, conducted at the institute Pasteur in Paris, France.
MPS IIIA gene therapy clinical trial:
Lysogene is conducting is an open-label, single arm, monocentric, phase I/II clinical study evaluating the tolerance and the safety of intracerebral administration of adeno-associated viral vector serotype 10 carrying the human SGSH and SUMF1 cDNAs for the treatment of Sanfilippo type A syndrome (P1-SAF-301). The Principal Investigator is Professor Marc Tardieu, Head of Unit, Neuropediatry, CHU Bicêtre, Le Kremlin-Bicêtre (France). Additional information about this clinical trial can be found at http://lysogene.com/en/approach/the-saf-301-program/p1-saf-301-clinical-trial or by visiting http://clinicaltrials.gov/ct2/show/NCT01474343.
BioMarin Pharmaceutical Inc. has concluded its Phase III study (MOR-004) for N-acetylgalactosamine 6-sulfatase (GALNS) for the treatment of Morquio A Syndrome (MPS IVA) and has applied for approval from the US FDA and Health Canada. Please click here to read BioMarin’s December 4, 2013 Press Release.
There were three Canadian sites involved with this trial: Montreal and Sherbrooke, Quebec and Toronto, Ontario, and an additional site in Calgary for an additional study investigating cardio-pulmonary effects of GALNS (MOR-008).
BioMarin’s MPS IV A program’s website (www.morquiobmrn.com) is a great place to look for current information. In addition to the MOR-004 and MOR-008 studies, BioMarin is also conducting an “under 5” study (MOR-005) and a “non-ambulatory” study (MOR-006).
Further information about BioMarin’s MPS IV A program is available at www.clinicaltrials.gov at this link: http://www.clinicaltrials.gov/ct2/show/NCT00787995?term=morquio&rank=2.
For additional medical questions related to MPS IV A and the clinical details of BioMarin’s program, please contact the Medical Director for BioMarin’s MPS IV A program, Celeste Decker, at email@example.com or 415-506-6469.
MPS IV B Registry:
The Canadian MPS Society, through its MPS IV B Fund, is funding a Registry for MPS IV B/late-onset GM-1 Gangliosidosis. For more information, please visit www.morquiob.org.
The U.S. Food and Drug Administration (FDA) granted marketing approval for Naglazyme(TM) (galsulfase), enzyme replacement therapy (ERT) for the treatment of MPS VI, on June 1, 2005. BioMarin received licensing approval for Naglazyme in Canada this September (2013). For more information please contact BioMarin Pharmaceutical Inc., Commercial Operations at: 1-415-506-6700.
In August 2013, Ultragenyx Pharmaceutical Inc. received Approval of its Clinical Trial Application for a Phase I/II Trial Testing UX003 in Mucopolysaccharidosis Type VII (MPS VII). The company expects to start enrolling patients later this year at a single center in the U.K. If the Phase 1/2 trial is successful, the company anticipates it would proceed with a pivotal Phase 3 trial in 2014. Click here to read the company's press release regarding this study. For more information, visit www.ultragenyx.com.
Enzyme Replacement Therapy
MYOZYME® (alglucosidase alfa), a recombinant form of human acid alpha-glucosidase (GAA), was approved by Health Canada on August 14, 2006 for the treatment of patients with Pompe disease (GAA deficiency). The approval of MYOZYME represents a significant milestone in the management of Canadian patients with Pompe disease as it is the first etiology specific therapy for this rare, rapidly progressing, and often fatal disease.
All patients with Pompe disease have an inherited deficiency of the enzyme GAA, which works optimally in the lysosome to convert glycogen to glucose. GAA deficiency lead to glycogen accumulation in, and eventually rupture of, the lysosome resulting in cellular dysfunction, particularly in cardiac, respiratory, and skeletal muscle tissue.
Prior to the approval of MYOZYME there was no approved treatment for Pompe disease that focused on the cause of the disease. Palliative and supportive care was the mainstay of treatment. The approval of MYOZYME will provide a therapeutic option for patients to manage this devastating disease.
CANADIAN ASSOCIATION OF POMPE (CAP)
The goal of CAP is to provide support for Canadians with Pompe disease and to raise awareness of Pompe disease in Canada and elsewhere. For more information, please visit http://www.pompecanada.com/.
Study of outcomes from transplants for Alpha-Mannosidosis
Dr. Martin Myranek from Hanover Medical School is conducting a study on the outcomes of transplants for Alpha-Mannosidosis. View the results at www.mannosidosis.org.
Clinical Trial of Enzyme Replacement Therapy for Alpha-Mannosidosis
The Scandinavian company Zymenex has been working for over 10 years to develop a number of Enzyme Replacement Therapies for Lysosomal diseases, including Mannosidosis. Please visit www.ISMRD.org for more information.